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Asifa S. Haider1,3 and Michelle A. Lowes1,3
Psoriasis is a chronic, debilitating, immune-mediated inflammatory skin disease. As IFN-g is involved in many
cellular processes, including activation of dendritic cells (DCs), antigen processing and presentation, cell
adhesion and trafficking, and cytokine and chemokine production, IFN-g–producing Th1 cells were proposed to
be integral to the pathogenesis of psoriasis. Recently, IFN-g was shown to enhance IL-23 and IL-1 production
by DCs and subsequently induce Th17 cells, which are important contributors to the inflammatory cascade
in psoriatic lesions. To determine whether IFN-g indeed induces the pathways expressed in psoriatic lesions,
a single intradermal injection of IFN-g was administered to an area of clinically normal, non-lesional (NL) skin of
psoriasis patients and biopsies were collected 24 hours later. Although there were no visible changes in the
skin, IFN-g induced many molecular and histological features characteristic of psoriatic lesions. IFN-g increased
a number of differentially expressed genes in the skin, including many chemokines concomitant with an influx
of T cells and inflammatory DCs. Furthermore, inflammatory DC products tumor necrosis factor (TNF), inducible
nitric oxide synthase, IL-23, and TNF-related apoptosis-inducing ligand were present in IFN-g–treated skin. Thus,
IFN-g, which is significantly elevated in NL skin compared with healthy skin, appears to be a key pathogenic
cytokine that can induce many features of the inflammatory cascade of psoriasis.
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INTRODUCTION
Psoriasis is an inflammatory skin disease affecting B2% of
the population of the United States, and is considered one of
the most prevalent cell-mediated inflammatory diseases
(Lebwohl, 2003). Psoriatic lesions are typically erythematous
scaly plaques, and patients are classified based on the
severity of their disease, with a gradient ranging from mild to
moderate-to-severe based on the body surface area involved.
Psoriatic lesions are characterized by increased infiltration of
both activated T cells and dendritic cells (DCs) compared
with normal or uninvolved (non-lesional, NL) psoriatic skin
(Lowes et al., 2007). Through the use of biological agents and
therapeutic treatments, many immune pathways involved in
psoriasis are being elucidated (Nograles et al., 2010).
Historically, psoriasis was considered to be a predomi-
nantly type-1, IFN-g–mediated disease, based on the signi-
ficant IFN-g genomic signature in lesional skin (LS; Lew et al.,
2004; Suarez-Farinas et al., 2010). Flow cytometric analysis
revealed overexpression of IFN-g in both circulating T cells
and those isolated from LS (Austin et al., 1999). In recent
years, focus has shifted to the role of IL-17 and the
contributions of Th17 cells to the pathogenesis of auto-
immunity. Although IFN-g inhibits the production of IL-17 by
T cells in vitro (Harrington et al., 2005; Park et al., 2005),
Th17 cells cultured with IL-12 are able to produce IFN-g
(Annunziato et al., 2007). The impact of the coproduction of
IL-17 and IFN-g has recently been underscored in a murine
model of diabetes, where Th17 cells become more patho-
genic once they acquired the ability to produce IFN-g
(Bending et al., 2009; Martin-Orozco et al., 2009). In human
autoimmune disease, Th1 and Th17 cells often coexist
(Aggarwal et al., 2003; Murphy et al., 2003; Langrish et al.,
2005; Annunziato et al., 2007). Our group has identified
a population of T cells that coproduce IFN-g and IL-17 in
psoriatic lesions (Lowes et al., 2008), induced by DCs
isolated from the dermis of psoriatic lesions, but not by
DCs from healthy skin (Zaba et al., 2009a). This difference in
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immunostimulatory potential has been attributed, in part, to
the presence of an additional population of CD11cþCD1c
inflammatory DCs that are found in psoriatic, but not healthy
skin (Zaba et al., 2009a). In situ, inflammatory DCs express
IL-23 and IL-12, which may potentially drive Th1/Th17 cell
responses (Lowes et al., 2005; Guttman-Yassky et al., 2008).
However, the initial stimulus for this cascade in situ is
currently unknown. Recent studies have implicated IFN-g as
a possible contributor, as it can program myeloid DCs to
produce IL-23 and IL-1, promoting IL-17 production by
memory T cells (Kryczek et al., 2008). Thus, the contributions
of IFN-g to the pathogenesis of psoriasis are now being
re-evaluated.
Before the discovery that IFN-g has a role in auto-
immunity, IFN-g was used as therapy for several diseases
including rheumatoid arthritis, psoriatic arthritis, psoriasis,
and lepromatous leprosy infections (Morhenn et al., 1987;
Cannon et al., 1989; Fierlbeck and Rassner, 1990; Fierlbeck
et al., 1990; Veys et al., 1997). Regular cutaneous injections
of IFN-g had some efficacy in the treatment of these diseases;
however, a subset of patients developed focal skin reactions
at the site of injection (Morhenn et al., 1987; Cannon et al.,
1989; Fierlbeck and Rassner, 1990; Fierlbeck et al., 1990;
Veys et al., 1997). Injection site reactions (often assessed
several weeks after starting IFN-g) were characterized
by induration, erythema, epithelial thickening, increased
expression of HLA-DR, and accumulation of T cells and
monocytes in the dermis (Nathan et al., 1986; Morhenn et al.,
1987; Barker et al., 1989, 1990; Fierlbeck and Rassner,
1990; Fierlbeck et al., 1990). These studies suggested that
prolonged exposure to IFN-g might initiate changes in the
skin that are consistent with a psoriatic phenotype, and thus
IFN-g may be involved in the initial development of psoriatic
lesions.
To address the role of IFN-g in the induction of the
inflammatory cascade in psoriasis and to identify the early
underlying changes that occur before the development of a
visible lesion, we analyzed responses to a single intradermal
injection of IFN-g at an early 24-hour time point in psoriasis
patients with mild disease (o10% body surface area) and
healthy volunteers. In psoriasis patients, IFN-g injections
were administered to an area of NL skin, which allowed
the early genomic and histological IFN-g responses to be
determined. Although there were no visible changes in the
skin, IFN-g induced a genomic signature and cellular
infiltration pattern that was similar to lesional psoriatic
skin. Many inflammatory cytokines and chemokines were
upregulated concurrent with increases in multiple dermal
cell populations, including CD3þ T cells and CD11cþ DCs.
Notably, inflammatory DCs (CD11cþCD1c) were increased
in the skin after IFN-g injection, in addition to enhanced
expression of their inflammatory products—tumor necrosis
factor (TNF), inducible nitric oxide synthase (iNOS),
IL-23p19, and TNF-related apoptosis-inducing ligand
(TRAIL). Furthermore, Ingenuity Pathway Analysis identified
pathways involved in lymphoid tissue development that were
enriched in the transcriptome of the skin after IFN-g injection.
IFN-g induced the lymphoid-organizing chemokine, CCL19,
and associated organization of T cells and DC clusters,
suggesting that IFN-g may induce lymphoid tissue neogenesis
before the development of visible lesions. Thus, this in vivo
study suggests that IFN-g can prime an inflammatory environ-
ment in the skin that has many features of psoriasis.
RESULTS
A single intradermal injection of IFN-c was biologically
active in the skin
To confirm that the injected IFN-g was biologically active, we
assessed HLA-DR, a protein known to be upregulated by
IFN-g after intradermal injection (Nathan et al., 1986, 1990).
There were increased HLA-DRþ cells in both normal and NL
skin after injection of IFN-g, but not in the placebo control,
indicating that the IFN-g was functional (Supplementary
Figure S1 online). Clinically, a single injection of IFN-g did
not induce the visible development of a psoriasis-like lesion
at the site of injection, as had been seen after a month of
repeated IFN-g injections (Fierlbeck and Rassner, 1990;
Fierlbeck et al., 1990). Histologically, epidermal thickness
was not altered by IFN-g injection in either group (Supple-
mentary Figure S2a online), and expression of keratin 16,
a measure of altered keratinocyte differentiation, was not
induced (Supplementary Figure S2b and c online). However,
there were marked genomic and cellular changes induced by
IFN-g in both the groups.
IFN-c–induced genomic changes in the skin consistent
with a psoriatic phenotype
Microarray analysis was performed to compare the IFN-g
response in healthy and psoriatic skin using fold change 42
and false discovery rate o0.01. The ‘IFN-g response’ was
defined as the differentially expressed genes (DEGs) in IFN-
g–treated skin compared with placebo for psoriasis patients
and healthy individuals. Using this definition, 706 unique
DEGs (964 probe sets) were upregulated and 547 DEGs (708
probe sets) were downregulated in healthy IFN-g–treated skin.
There were 775 upregulated DEGs (1055 probe sets) and
719 downregulated DEGs (900 probe sets) in IFN-g–treated
psoriatic skin (Supplementary Table S1 online). Although
the IFN-g response (fold change) of many genes was higher
in psoriasis than in healthy skin, these differences were not
statistically significant after correcting for multiple hypo-
theses with the Benjamini–Hochberg procedure. In addition,
there was very strong correlation in the response to IFN-g in
both the groups (r¼ 0.96; Supplementary Figure S3 online),
further supporting that there was no difference in IFN-g–
induced gene expression between healthy controls and
psoriasis patients. Therefore, hereafter, we present data
mostly from psoriatic NL skin.
IFN-g induced the expression of numerous genes in the
skin that are known to contribute to inflammation and that
have been implicated in the pathogenesis of psoriasis. A
selected list of inflammatory DEGs that are upregulated in
psoriasis (Suarez-Farinas et al., 2010), as well as after IFN-g
injection, is presented in Table 1. This list included cytokines
and chemokines, as well as other inflammatory products.
Expression of select known IFN-g–induced genes (CXCL9,
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CXCL10, CCL2, and CX3CL1) was verified by real-time PCR
(RT-PCR; Figure 1). Additional DEGs were confirmed by
RT-PCR, and the IFN-g response measured by RT-PCR was
strongly correlated with the microarray data (Supplementary
Figure S4 online). Furthermore, using gene set enrichment
analysis, four published psoriasis gene sets (Suarez-Farinas
et al., 2010) correlated with the IFN-g response in psoriasis
patients (Supplementary Table S2 online), indicating that
IFN-g can induce many genes that are present in psoriasis.
Ingenuity Pathway Analysis was also used to identify the
statistically significant biological functions represented by
these IFN-g–induced DEGs (Supplementary Table S2 online).
The top functions represented by the upregulated DEGs after
IFN-g injection were consistent with the pathways involved
Table 1. Microarray fold change values of select inflammatory genes upregulated in skin after IFN-c injection
compared with placebo
/
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in psoriasis, including inflammatory response, inflammatory
disease, cellular movement and development, immune cell
trafficking, and cell-mediated immune responses. Thus, the
IFN-g response in skin reflects an inflammatory molecular
phenotype.
IFN-c–induced T cells and inflammatory myeloid DCs
infiltration into the skin
Given the upregulation of many chemokines by IFN-g, we
evaluated the cellular infiltrates induced by IFN-g in the skin.
Previous studies have found an increased number of T cells in
the skin 3 days after repeated IFN-g injections (Nathan et al.,
1986, 1990). Here, we showed that even 24 hours post IFN-g
injection, there was a significantly increased number of
CD3þ T cells in the skin (Supplementary Figure S5 online).
DCs and their inflammatory products have also been
implicated in the pathogenesis of psoriasis. Thus, we sought
to determine whether IFN-g induced the infiltration of DCs
into skin. We have previously classified CD11cþCD1cþ
DCs in normal skin as ‘resident’ DCs. In psoriatic LS, an
additional population of inflammatory DCs, which express
CD11c, but not CD1c, are present (Zaba et al., 2009a). IFN-g
induced greater numbers of CD11cþ DCs in the skin,
whereas CD1cþ DCs remained constant throughout all
the samples analyzed (Figure 2a and b). As there is no
exclusive marker for inflammatory DCs, an approximation of
their numbers can be calculated by subtracting the number of
CD1cþ DCs from the number CD11cþ cells (Johnson-Huang
et al., 2010). Figure 2c shows significantly increased numbers
of CD11cþCD1c inflammatory DCs in both normal and
NL skin only after IFN-g injection. To further analyze these
cells, we performed two-color immunofluorescence with
antibodies against CD11c and CD1c. Although the majority
of CD11cþ cells in the placebo-treated skin co-expressed
CD1c (yellow cells), a large proportion of CD11cþ cells in
IFN-g–treated skin were CD1c negative (Figure 2d), confirm-
ing the presence of inflammatory DCs. We have previously
generated a list of DEGs specific for psoriatic inflammatory
CD1c DCs (Zaba et al., 2010). Using gene set enrichment
analysis, the inflammatory CD1c DC DEGs were highly
enriched in the IFN-g response genes (Supplementary Table
S2 online; enrichment score¼0.38, normalized enrichment
score¼ 1.8, Po0.0001, for both the groups). Thus, IFN-g can
induce the accumulation of inflammatory DCs, both at the
cellular and genomic levels, even in normal skin where they
are typically absent.
IFN-c–induced products of inflammatory myeloid DCs
in the skin
Inflammatory DCs in psoriasis have been previously shown to
produce inflammatory mediators, including TNF, iNOS,
IL-12/23p40, and IL-23p19, and express TNFSF10/TRAIL—
a putative new marker of inflammatory DCs (Lowes et al.,
2005; Zaba et al., 2007, 2010; Guttman-Yassky et al., 2008).
To determine whether the DCs induced by IFN-g could be
functioning as inflammatory DCs, we assessed the presence
of these inflammatory products. Gene expression of
TNFSF10/TRAIL is elevated by IFN-g (Table 1), and, similarly,
immunofluorescent labeling identified many CD11cþ
cells in the skin co-express TRAILþ after IFN-g injection
(Figure 3a). In comparison with baseline and placebo
controls, which had minimal TNF and iNOS staining,
co-expression of these mediators with CD11cþ DCs was
increased in IFN-g–treated skin (Figure 3b and c). In addition,
by using RT-PCR, we detected a significant increase in
IL-23p19 messenger RNA (mRNA) expression in the skin after
IFN-g injection, and a trend toward increased IL-12p35 and
IL-12/23p40 (Figure 3d). These data are in line with a recent
study that described a role of IFN-g in priming DCs ex vivo
to produce IL-23 (Kryczek et al., 2008). This in vitro priming
stimulated IL-17 production by T cells, and thus we assessed
expression of IL17A mRNA in the skin after IFN-g injection
by RT-PCR. Despite increased levels of IL-23 after IFN-g
injection, we did not find mRNA expression of IL17, or two
IL-17-regulated genes CCL20 and DEFB4, in the skin (data
not shown). As biopsies were taken only 24 hours after the
injection of IFN-g, there may not have been sufficient time to
induce a Th17 cell response in NL skin. Taken together, these
findings further suggest that IFN-g primes an inflammatory
environment.
Molecules involved in ectopic lymphoid neogenesis were
induced by IFN-c
During chronic inflammation, ectopic lymphoid tissue
develops in the peripheral non-lymphoid organs (Aloisi and
Pujol-Borrell, 2006). Previously, on the basis of analysis of
upregulated DEGs, the existence of these structures within
psoriatic LS skin has been proposed (Lew et al., 2004). In
addition, organized clusters of T cells and DCs are often seen
in LS skin (Lowes et al., 2007). Ingenuity Pathway Analysis
biological function pathways of lymphoid tissue structure
and development, hematological system development and
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Figure 1. IFN-c injection induces genomic expression of known
IFN-c–regulated chemokines. mRNA expression levels normalized to human
acidic ribosomal protein (hARP) for the T-cell (CXCL9 and CXCL10) and
dendritic cell (DC; CCL2 and CX3CL1) chemokines in baseline, placebo,
and IFN-g-injected healthy (black bars, n¼ 10) and psoriatic skin (white bars,
n¼ 10). Error bars represent the mean±SEM. IFN-g-injected skin was
compared with placebo. **Po0.01.
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function, tissue morphology, and hematopoiesis were signi-
ficantly represented by the IFN-g–induced genes (Supple-
mentary Table S2 online). Genes involved in the ectopic
lymphoid neogenesis were further investigated by RT-PCR
and protein staining. Lymphotoxin-b, which is critical in the
development of lymphoid structures (De Togni et al., 1994;
Banks et al., 1995; Futterer et al., 1998), was elevated by IFN-
g (Figure 4a). Lymphoid tissue–organizing chemokines,
CXCL12/SDF-1, CXCL13, and CCL21, were also assessed,
but were unchanged by IFN-g (Supplementary Figure S4
online). IFN-g did, however, increase the expression of
CXCR4, the receptor for CXCL12/SDF-1, as well as regulator
of G protein signaling 16, which is involved in the retention
of CXCR4þ cells at sites of inflammation (Hsu et al., 2008).
CCL19, an important factor involved in the organization of
T cells and DCs (Fukuyama et al., 2006), was significantly
increased by IFN-g (Figure 4a). Consistent with CCL19
upregulation, CD11cþ DCs and CD3þ T cells in IFN-g-
injected skin were organized in clusters reminiscent of the
T-cell zones of lymph nodes (Figure 4b). The development
of lymphoid tissue is also associated with high endothelial
venules marked by peripheral node addressin, and IFN-g
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Figure 2. IFN-c injection induces dermal inflammatory myeloid dendritic cells (DCs). Representative immunohistochemistry of (a) CD11cþ and
(b) CD1cþ cells in psoriatic skin. (c) Quantification of CD11cþ , CD1cþ , and inflammatory DCs (CD11cþ minus CD1cþ cells) in healthy (black circles)
and psoriatic skin (white circles). Each circle represents a different patient. IFN-g-injected skin is compared with placebo. ***Po0.001. (d) Two-color
immunofluorescence of CD1cþ DCs (red) and CD11cþ DCs (green). The white line delineates the dermal–epidermal junction. Bar¼100 mm.
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enhanced the expression of peripheral node addressin in the
skin (Figure 4c). Finally, at both the mRNA (Table 1) and
protein (Figure 4d) levels, IFN-g induced the expression of
ICAM-1 and VCAM-1, adhesion molecules found in second-
ary and tertiary lymphoid organs. Taken together, these data
suggest that IFN-g may indeed induce some facets of ectopic
lymphoid neogenesis in the skin.
IFN-c as a biomarker of psoriasis disease potential and/or
severity
The molecular and histological responses to IFN-g injection
were similar between healthy and psoriatic skin. This finding
suggested that the difference between psoriatic patients
and controls might be upstream of the ‘‘response’’ to IFN-g,
potentially in the induction of IFN-g, with psoriatic patients
having a lower threshold for IFN-g production than the
healthy controls. To address this question, IFN-g mRNA
expression was compared across NL and LS skin of patients
with varying severities of psoriasis, from mild psoriasis (this
study) to moderate-to-severe psoriasis, published previously
(Johnson-Huang et al., 2010). The lowest level of IFN-g
expression was found in healthy skin, with an increasing
gradient of IFN-g mRNA expression as disease severity
worsened. IFN-g expression was significantly increased in
NL skin from moderate-to-severe psoriasis patients compared
with mild NL skin, and was highest in LS psoriatic skin
(Figure 5a). Moreover, an intradermal injection of IFN-g into
mild NL skin induced IFN-gmRNA at a level between NL and
LS skin of moderate-to-severe patients.
To evaluate whether the level of IFN-g mRNA in the skin
correlated with a downstream genomic effect, we analyzed
two lists of DEGs from comparison of NL versus healthy skin
by Ingenuity Pathway Analysis. The IFN signaling path-
way was significantly represented (P¼0.03) by DEGs in
moderate-to-severe NL skin (Zaba et al., 2009b), but not by
DEGs in mild NL skin compared with healthy skin. For com-
parison, the IFN signaling pathway was also significantly
represented by the DEGs in IFN-g–treated NL skin (Po109).
The range of IFN-g expression and activation of downstream
signaling molecules, based on disease severity, suggests that
IFN-g may be a useful biomarker of psoriasis disease
potential.
We also compared cell counts across the range of disease
states and showed that CD3þ T cells and CD11cþCD1c
inflammatory DCs followed a similar pattern, with an
increase in cells as disease severity worsened (Figure 5b).
The patterns of increasing cellularity and IFN-g mRNA
expression with psoriasis disease progression were associated
with an enrichment of psoriasis genes in the IFN-g response
DEGs (by gene set enrichment analysis). Thus, we sought to
determine how the IFN-g response genes compared with
moderate-to-severe NL and LS psoriasis. Using unsupervised
hierarchical clustering, we found that there were two main
clusters of samples: (1) healthy skin samples clustered with
NL skin and (2) IFN-g–treated skin clustered with LS psoriatic
skin (Supplementary Figure S6 online). Taken together,
these data suggest that injection of IFN-g may induce an
inflammatory state with some features of LS psoriatic skin.
DISCUSSION
Factors that induce the progression of psoriatic NL skin into
LS skin, and why some patients have more severe disease
than others are still unclear. Here, we have analyzed the
molecular and cellular changes that occur in the skin in
response to IFN-g, and found that a single intradermal
injection of IFN-g induced an inflammatory environment in
both healthy and psoriatic skin. We showed upregulation of
many chemokines and inflammatory cytokines, as well as the
influx of inflammatory cells, most notably T cells and
inflammatory DCs. In addition, IFN-g induced features of
lymphoid tissue, including organization of T-cell and DC
clusters. At the genomic level, psoriasis gene sets (DEGs in LS
skin compared with NL) (Suarez-Farinas et al., 2010) were
highly enriched in the IFN-g response genes, indicating a
significant degree of overlap of these genes. Thus, the
inflammatory response induced by IFN-g in the skin
resembled some of the changes that occur in psoriatic
lesions.
The observation that the response to IFN-g was similar in
both NL psoriatic skin and healthy skin indicates that the
pathogenic etiology in psoriasis is not in the ‘‘response’’ to
IFN-g per se, but may be further upstream. Conceivably, the
threshold to produce IFN-g may be different between healthy
controls and psoriasis patients. Consistently, elevated IFN-g
expression has been found in NL psoriatic skin compared
with healthy skin (Uyemura et al., 1993; Guttman-Yassky
et al., 2008; Kryczek et al., 2008). Here, we also show that
IFN-g mRNA expression increased, even in NL skin, as
psoriasis became more severe, suggesting that psoriasis
patients have a greater propensity to produce IFN-g than
the healthy controls. The increase in IFN-g expression in
psoriasis patients has been linked to polymorphisms in the IL4
and IL13 genes, resulting in the hypofunction of these IFN-
g–inhibitory cytokines (Elder, 2009).
Which cells contribute to the elevated expression of IFN-g
in NL compared with healthy skin is not known. Slightly
increased numbers of activated CD4þ and CD8þ T cells
have been found in NL skin (Baker et al., 1984; Placek et al.,
1988), which may account for augmented IFN-g. Here, we
also show that as psoriasis progresses, the numbers of CD3þ
Figure 3. IFN-c injection induces expression of known products of inflammatory myeloid dendritic cells (DCs). Two-color immunofluorescence of
CD11cþ DCs with inflammatory products: (a) tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), (b) TNF, and (c) inducible nitric oxide
synthase (iNOS) in baseline, placebo, and IFN-g-injected psoriatic skin. The white line delineates the dermal–epidermal junction. Bar¼100 mm. (d) mRNA
expression levels normalized to human acidic ribosomal protein (hARP) for additional DC cytokines in healthy (black bars, n¼10) and psoriatic skin
(white bars, n¼ 10). Error bars represent the mean±SEM. IFN-g-injected skin is compared with placebo. *Po0.05, **Po0.01.
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T cells in NL skin increase, with the highest numbers being
in LS skin (Figure 5b), consistent with previous reports (Bos
et al., 1983; Krueger, 2002). Additional cell types may also be
contributing to the elevated IFN-g. A significant proportion
of mast cells in NL skin showed positive IFN-g staining
(Ackermann et al., 1999). Neutrophils have also been
implicated as a source of IFN-g (Ethuin et al., 2004), although
they are rare in NL skin. In addition, keratinocytes in NL skin
express CD1d, which can stimulate CD161þ NK-T cells to
produce large amounts of IFN-g (Bonish et al., 2000). In
another genomic study comparing NL skin to healthy skin,
Gudjonsson et al. (2009) showed that innate defense genes
are elevated in NL skin, raising the possibility that psoriatic
NL skin may be ‘‘pre-activated’’. Despite these changes, not
all NL skin evolves into LS skin, indicating that a secondary
trigger, perhaps coupled with the presence of factors like IFN-
g, may induce lesion formation in psoriatic skin, but not in
healthy individuals who lack IFN-g.
Previous studies using a skin organ culture system where
NL psoriatic skin was cultured in vitrowith IFN-g showed that
the epidermal changes induced by IFN-g were partially
mediated by IL-1b (Wei et al., 1999). In this study, although
there was abundant DC infiltration and cytokine production
(including IL-1b and IL-23), with concomitant T-cell infiltra-
tion after IFN-g injection, these changes were insufficient to
induce full plaque development, possibly because there was
no Th17 cell cytokine production. The fact that the epidermis
was not altered by this regime of IFN-g is consistent with the
lack of IL-17. The dose of IFN-g may be insufficient for the
induction of T-cell responses or the early 24 hours time point
may not have allowed enough time to induce T-cell activa-
tion and polarization, and if biopsies were taken at later time
points, the T-cell phenotype may have been altered. Along
these lines, previous reports found that epidermal changes
and visible lesions resulted after a month of continuous IFN-g
injections (Nathan et al., 1986; Morhenn et al., 1987; Barker
et al., 1989, 1990; Fierlbeck and Rassner, 1990; Fierlbeck
et al., 1990), although the induction of IL-17 and IL-22 was
not assessed in these studies.
In conclusion, the present study strengthens the hypothesis
that IFN-g is a crucial mediator of skin inflammation.
Although this study examines the effect of IFN-g only in
healthy and psoriasis patients, it may provide a framework for
evaluating other diseases where IFN-g is considered to have a
major pathogenic role (Dardalhon et al., 2008).
MATERIALS AND METHODS
Study design and skin biopsies
We conducted a research study under a Rockefeller University
Institutional Review Board–approved protocol in which healthy
volunteers and patients with mild psoriasis (n¼ 10 per group)
received single intradermal injections of IFN-g (Actimmune,
1 106 IU) and saline (placebo) in areas of the skin that were
clinically normal (NL skin). Saline was used as a control, as the
inactive components of the Actimmune solution were not available.
After 24 hours, biopsies of both the sites were taken; biopsies at
baseline were also taken before injections. Each biopsy was cut into
two: half was stored in optimum cutting temperature for cryosections
and the other half was snap-frozen in liquid nitrogen for RNA
extractions. Written informed consent was obtained and the study
was performed in adherence with the Declaration of Helsinki
Principles. NL and LS tissue biopsies (n¼ 9 pairs) from moderate-
to-severe psoriasis patients were obtained under a Rockefeller
University Institutional Review Board–approved protocol (NCT ID:
00220025), which has been previously published (Johnson-Huang
et al., 2010).
Immunostaining
Skin sections were stained for immunohistochemistry and immuno-
fluorescence as previously described (Fuentes-Duculan et al., 2010).
All the antibodies used for staining are listed in Supplementary
Table S3 online.
mRNA extraction and RT-PCR
RNA extraction and RT-PCR using Taqman gene expression assays
(Supplementary Table S4 online) were performed as previously
described (Chamian et al., 2005). Custom primers for IFN-g and
IL-12/23p40 were generated as previously described (Chamian et al.,
2005). Data normalized to hARP housekeeping gene were quantified
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Figure 5. The gradient of IFN-c mRNA expression parallels T-cell
and dendritic cell (DC) infiltration as psoriasis becomes more severe.
(a) IFN-g mRNA expression in healthy (n¼ 10), non-lesional (NL) skin from
mild (n¼ 10, body surface area (BSA) o10%) versus moderate-to-severe
(n¼9, BSA410%) psoriasis patients, IFN-g-injected healthy (n¼ 10) or mild
NL psoriatic (n¼ 10) skin, and psoriatic lesional (LS; n¼ 9) skin. Error bars
represent the mean±SEM. **Po0.01. ***Po0.001. (b) Quantification of
CD3þ T cell (blue bars) and CD11cþCD1c inflammatory DC (red bars)
counts per mm of skin in patients in a. Mod, moderate; NS, nonsignificant.
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by software provided with Applied Biosystems (Carlsbad, CA) PRISM
7700 (Sequence Detection Systems, version 1.7). Normalized PCR
data were log2 transformed before statistical analysis.
Microarray hybridization
Human Genome U133 2.0. arrays (Affymetrix, Santa Clara, CA)
were used. See Supplemental Materials and Methods for details.
Statistical analysis
For comparison of RT-PCR data and cell counts from IFN-g-injected
skin versus respective placebo-treated skin, the Wilcoxon matched
pairs test was used. Mann–Whitney U test was used to compare
unpaired moderate-to-severe NL and LS with IFN-g– or placebo–-
treated skin. A P-value o0.05 was considered significant.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This research was supported by a pilot project grant to ASH (Clinical and
Translational Science Award grant UL 1RR024143); the Doris Duke
Foundation supported LMJ-H and MAL; NIH K23 AR052404 also supported
MAL; LMJ-H is also supported by the Linda and Leonard Berkowitz
Postdoctoral Fellowship.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Ackermann L, Harvima IT, Pelkonen J et al. (1999) Mast cells in psoriatic
skin are strongly positive for interferon-gamma. Br J Dermatol 140:
624–33
Aggarwal S, Ghilardi N, Xie MH et al. (2003) Interleukin-23 promotes a
distinct CD4 T cell activation state characterized by the production of
interleukin-17. J Biol Chem 278:1910–4
Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory
diseases. Nat Rev Immunol 6:205–17
Annunziato F, Cosmi L, Santarlasci V et al. (2007) Phenotypic and functional
features of human Th17 cells. J Exp Med 204:1849–61
Austin LM, Ozawa M, Kikuchi T et al. (1999) The majority of epidermal
T cells in Psoriasis vulgaris lesions can produce type 1 cytokines,
interferon-gamma, interleukin-2, and tumor necrosis factor-alpha,
defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a
type 1 differentiation bias is also measured in circulating blood T cells in
psoriatic patients. J Invest Dermatol 113:752–9
Baker BS, Swain AF, Fry L et al. (1984) Epidermal T lymphocytes and HLA-DR
expression in psoriasis. Br J Dermatol 110:555–64
Banks TA, Rouse BT, Kerley MK et al. (1995) Lymphotoxin-alpha-deficient
mice. Effects on secondary lymphoid organ development and humoral
immune responsiveness. J Immunol 155:1685–93
Barker JN, Allen MH, MacDonald DM (1989) The effect of in vivo interferon-
gamma on the distribution of LFA-1 and ICAM-1 in normal human skin.
J Invest Dermatol 93:439–42
Barker JN, Allen MH, MacDonald DM (1990) Alterations induced in
normal human skin by in vivo interferon-gamma. Br J Dermatol 122:
451–8
Bending D, De La Pena H, Veldhoen M et al. (2009) Highly purified Th17
cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID
recipient mice. J Clin Invest 119:565–72
Bonish B, Jullien D, Dutronc Y et al. (2000) Overexpression of CD1d by
keratinocytes in psoriasis and CD1d-dependent IFN-gamma production
by NK-T cells. J Immunol 165:4076–85
Bos JD, Hulsebosch HJ, Krieg SR et al. (1983) Immunocompetent cells
in psoriasis. In situ immunophenotyping by monoclonal antibodies.
Arch Dermatol Res 275:181–9
Cannon GW, Pincus SH, Emkey RD et al. (1989) Double-blind trial of
recombinant gamma-interferon versus placebo in the treatment of
rheumatoid arthritis. Arthritis Rheum 32:964–73
Chamian F, Lowes MA, Lin SL et al. (2005) Alefacept reduces infiltrating
T cells, activated dendritic cells, and inflammatory genes in psoriasis
vulgaris. Proc Natl Acad Sci USA 102:2075–80
Dardalhon V, Korn T, Kuchroo VK et al. (2008) Role of Th1 and Th17 cells in
organ-specific autoimmunity. J Autoimmun 31:252–6
De Togni P, Goellner J, Ruddle NH et al. (1994) Abnormal development of
peripheral lymphoid organs in mice deficient in lymphotoxin. Science
264:703–7
Elder JT (2009) Genome-wide association scan yields new insights into the
immunopathogenesis of psoriasis. Genes Immun 10:201–9
Ethuin F, Gerard B, Benna JE et al. (2004) Human neutrophils produce
interferon gamma upon stimulation by interleukin-12. Lab Invest
84:1363–71
Fierlbeck G, Rassner G (1990) Treatment of psoriasis and psoriatic arthritis
with interferon gamma. J Invest Dermatol 95:138S–41S
Fierlbeck G, Rassner G, Muller C (1990) Psoriasis induced at the injection site
of recombinant interferon gamma. Results of immunohistologic inves-
tigations. Arch Dermatol 126:351–5
Fuentes-Duculan J, Suarez-Farinas M, Zaba LC et al. (2010) A subpopulation
of CD163-positive macrophages is classically activated in psoriasis.
J Invest Dermatol 130:2412–22
Fukuyama S, Nagatake T, Kim DY et al. (2006) Cutting edge: uniqueness of
lymphoid chemokine requirement for the initiation and maturation
of nasopharynx-associated lymphoid tissue organogenesis. J Immunol
177:4276–80
Futterer A, Mink K, Luz A et al. (1998) The lymphotoxin beta receptor controls
organogenesis and affinity maturation in peripheral lymphoid tissues.
Immunity 9:59–70
Gudjonsson JE, Ding J, Li X et al. (2009) Global gene expression analysis
reveals evidence for decreased lipid biosynthesis and increased
innate immunity in uninvolved psoriatic skin. J Invest Dermatol
129:2795–804
Guttman-Yassky E, Lowes MA, Fuentes-Duculan J et al. (2008) Low
expression of the IL-23/Th17 pathway in atopic dermatitis compared to
psoriasis. J Immunol 181:7420–7
Harrington LE, Hatton RD, Mangan PR et al. (2005) Interleukin 17-producing
CD4+ effector T cells develop via a lineage distinct from the T helper
type 1 and 2 lineages. Nat Immunol 6:1123–32
Hsu HC, Yang P, Wang J et al. (2008) Interleukin 17-producing T helper cells
and interleukin 17 orchestrate autoreactive germinal center development
in autoimmune BXD2 mice. Nat Immunol 9:166–75
Johnson-Huang LM, Suarez-Farinas M, Sullivan-Whalen M et al. (2010)
Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17
axis in normalized psoriasis plaques. J Invest Dermatol 130:2654–63
Krueger JG (2002) The immunologic basis for the treatment of psoriasis with
new biologic agents. J Am Acad Dermatol 46:1–23; quiz -6
Kryczek I, Bruce AT, Gudjonsson JE et al. (2008) Induction of IL-17+ T cell
trafficking and development by IFN-gamma: mechanism and patho-
logical relevance in psoriasis. J Immunol 181:4733–41
Langrish CL, Chen Y, Blumenschein WM et al. (2005) IL-23 drives a patho-
genic T cell population that induces autoimmune inflammation. J Exp
Med 201:233–40
Lebwohl M (2003) Psoriasis. Lancet 361:1197–204
Lew W, Bowcock AM, Krueger JG (2004) Psoriasis vulgaris: cutaneous
lymphoid tissue supports T-cell activation and ‘Type 10 inflammatory
gene expression. Trends Immunol 25:295–305
Lowes M, Bowcock AM, Krueger J (2007) Pathogenesis and therapy of
psoriasis. Nature 445:866–73
Lowes MA, Chamian F, Abello MV et al. (2005) Increase in TNF-alpha and
inducible nitric oxide synthase-expressing dendritic cells in psoriasis and
1186 Journal of Investigative Dermatology (2012), Volume 132
LM Johnson-Huang et al.
IFN-g Induces an Inflammatory State
reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA
102:19057–62
Lowes MA, Kikuchi T, Fuentes-Duculan J et al. (2008) Psoriasis vulgaris
lesions contain discrete populations of Th1 and Th17 T cells. J Invest
Dermatol 128:1207–11
Martin-Orozco N, Chung Y, Chang SH et al. (2009) Th17 cells promote
pancreatic inflammation but only induce diabetes efficiently in lympho-
penic hosts after conversion into Th1 cells. Eur J Immunol 39:216–24
Morhenn VB, Pregerson-Rodan K, Mullen RH et al. (1987) Use of
recombinant interferon gamma administered intramuscularly for the
treatment of psoriasis. Arch Dermatol 123:1633–7
Murphy CA, Langrish CL, Chen Y et al. (2003) Divergent pro- and anti-
inflammatory roles for IL-23 and IL-12 in joint autoimmune inflamma-
tion. J Exp Med 198:1951–7
Nathan C, Squires K, Griffo W et al. (1990) Widespread intradermal
accumulation of mononuclear leukocytes in lepromatous leprosy
patients treated systemically with recombinant interferon gamma. J Exp
Med 172:1509–12
Nathan CF, Kaplan G, Levis WR et al. (1986) Local and systemic effects of
intradermal recombinant interferon-gamma in patients with lepromatous
leprosy. N Engl J Med 315:6–15
Nograles KE, Davidovici B, Krueger JG (2010) New insights in the
immunologic basis of psoriasis. Semin Cutan Med Surg 29:3–9
Park H, Li Z, Yang XO et al. (2005) A distinct lineage of CD4 T cells regulates
tissue inflammation by producing interleukin 17. Nat Immunol 6:1133–41
Placek W, Haftek M, Thivolet J (1988) Sequence of changes in psoriatic
epidermis. Immunocompetent cell redistribution precedes altered
expression of keratinocyte differentiation markers. Acta Derm Venereol
68:369–77
Suarez-Farinas M, Lowes MA, Zaba LC et al. (2010) Evaluation of the psoriasis
transcriptome across different studies by gene set enrichment analysis
(GSEA). PLoS One 5:e10247
Uyemura K, Yamamura M, Fivenson DF et al. (1993) The cytokine network
in lesional and lesion-free psoriatic skin is characterized by a T-helper
type 1 cell-mediated response. J Invest Dermatol 101:701–5
Veys EM, Menkes CJ, Emery P (1997) A randomized, double-blind study
comparing twenty-four-week treatment with recombinant interferon-
gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis
Rheum 40:62–8
Wei L, Debets R, Hegmans JJ et al. (1999) IL-1 beta and IFN-gamma induce
the regenerative epidermal phenotype of psoriasis in the transwell skin
organ culture system. IFN-gamma up-regulates the expression of keratin
17 and keratinocyte transglutaminase via endogenous IL-1 production.
J Pathol 187:358–64
Zaba L, Cardinale I, Gilleaudeau P et al. (2007) Amelioration of epidermal
hyperplasia by TNF inhibition is associated with reduced Th17
responses. J Exp Med 204:3183–94
Zaba LC, Fuentes-Duculan J, Eungdamrong NJ et al. (2009a) Psoriasis is
characterized by accumulation of immunostimulatory and Th1/Th17
cell-polarizing myeloid dendritic cells. J Invest Dermatol 129:79–88
Zaba LC, Fuentes-Duculan J, Eungdamrong NJ et al. (2010) Identification
of TNF-related apoptosis-inducing ligand and other molecules that
distinguish inflammatory from resident dendritic cells in patients with
psoriasis. J Allergy Clin Immunol 125:1261–8 e9
Zaba LC, Suarez-Farinas M, Fuentes-Duculan J et al. (2009b) Effective
treatment of psoriasis with etanercept is linked to suppression of IL-17
signaling, not immediate response TNF genes. J Allergy Clin Immunol
124:1022–10 e1-395
www.jidonline.org 1187
LM Johnson-Huang et al.
IFN-g Induces an Inflammatory State
